Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation

Uyar B. S. , Ensarioğlu K., Kurt E. B. , Özkan D., Güneş S. Ö.

Turkish Journal of Anaesthesiology and Reanimation, vol.50, no.3, pp.228-231, 2022 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 50 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.5152/tjar.2021.20450
  • Journal Name: Turkish Journal of Anaesthesiology and Reanimation
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.228-231
  • Keywords: Antifibrotic, COVID-19, pirfenidone, pulmonary fibrosis, respiratory distress


© 2022, AVES. All rights reserved.Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.